What is the risk of uveitis flare in patients with JIA and uveitis, who are in remission, when tapering medications?

The ADJUST Trial is in progress and is trying to answer precisely this question for those currently receiving adalimumab. I am not aware currently of a large database to provide a reliable answer to this question. My approach is to require no evidence for active uveitis for at least 12 months, and t...